Overview

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Status:
Completed

Trial end date:
2018-12-05

Target enrollment:

Participant gender:

Summary

This trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A.

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Factor VIII